Last reviewed · How we verify

NCT07175688

Metabolic Associated Fatty Liver Disease and Pancreatic Steatosis in Obese Versus Lean Chronic Hepatitis B Patients

Completed Last updated 16 September 2025
What this trial tests

trial testing Abdominal Ultrasound in Metabolic Associated Fatty Liver Disease in 217 participants. Completed in 1 January 2024.

Timeline
10 April 2022
Primary endpoint
1 January 2024
1 January 2024

Quick facts

Lead sponsorTanta University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment217
Start date10 April 2022
Primary completion1 January 2024
Estimated completion1 January 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

18 and older, any sex, with Metabolic Associated Fatty Liver Disease or Pancreatic Steatosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to evaluate the prevalence of metabolic associated fatty liver disease (MAFLD), fatty pancreas and hepatic fibrosis in obese and lean patients with chronic hepatitis B; either treatment naive or on treatment with first-line nucleos(t)ide analogs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Abdominal Ultrasound

Trials testing the same drug.

Other recruiting trials for Metabolic Associated Fatty Liver Disease

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07175688.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing